Danube AG/ CH1216478797 /
2024-05-22 12:38:00 PM | Chg. +1.7500 | Volume | Bid7:16:09 PM | Ask7:16:09 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
109.4000EUR | +1.63% | 311 Turnover: 33,997.4000 |
108.5000Bid Size: 65 | 108.9500Ask Size: 65 | 28.7 bill.EUR | 2.31% | 11.84 |
GlobeNewswire
2022-02-07
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer
GlobeNewswire
2021-07-28
Verisk’s AIR Worldwide Estimates Insured Losses for July Floods in Germany Could Approach EUR 5 Bill...
GlobeNewswire
2021-07-02
Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial
GlobeNewswire
2021-04-23
Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment
GlobeNewswire
2021-01-19
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appoin...
GlobeNewswire
2020-12-15
Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis
GlobeNewswire
2020-09-08
Harvesting a new transport channel: the latest Top Story available on CNHIndustrial.com
GlobeNewswire
2020-07-08
Crystal River Cruises Named #1 River Cruise Line in Travel + Leisure's 2020 World's Best Awards
GlobeNewswire
2020-04-08
Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDA